TP53 and hepatocellular carcinoma: In this study, we discovered that MCB1 drove HCC initiation and chemoresistance by downregulating the expression of p53 and TKI targets, which suggests that MCB1 could be a novel biomarker for early HCC diagnosis and individualized therapy.